Patients On Belviq Developing Cancer File Lawsuits Against Responsible Drug Company For Failure To Warn
The Belviq recall was announced in February 2020 after the FDA concluded that the potential risk of cancer associated with Belviq (lorcaserin) outweighs its benefits. The FDA noted there was a numerical imbalance in the number of patients on Belviq developing cancer, then pointed out pancreatic cancer, colorectal cancer, and lung cancer, in particular. Following this Belviq recall some of those patients on Belviq developing cancer filed Belviq lawsuits alleging a failure to warn about the risk of cancer associated with Belviq.
As according to the responsible drug company, Eisai, Inc., on its Belviq.com website:
BELVIQ was approved in June 2012 by the FDA as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related co-morbid condition, and was launched in the United States in June 2013.
Beginning in early 2020 the weight-loss medicine Belviq was the subject of drug-safety scrutiny by the FDA, as we reported in these earlier articles about Belviq:
- Belviq Cancer Risk Warning Alert Issued To Patients And Doctors In January 2020 FDA Drug Safety Communication
Recent Clinical Trial Findings Suggest Use Of The Weight-Loss Medicine Belviq Increased Risk Of Cancers
- Belviq Recall: FDA Warning Cancer Risks Of Diet Drug Belviq Outweigh Benefits -- February 2020
Excess Cases Of Pancreatic Cancer, Colon Cancer, Rectal Cancer, And Lung Cancer Observed In Belviq Safety Clinical Trial
Strictly Confidential, No Obligation.
For more information relevant to the Belviq lawsuits being filed against the drug company Eisai for failure to warn following the Belviq recall, we direct you to this February 13, 2020, FDA Drug Safety Communication: "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market".
Essentially, the message from the FDA is that document is the potential risk of cancer associated with Belviq outweighs the benefits of this weight-loss medicine. In more detail, an imbalance in specific cancers including pancreatic, colorectal, and lung contributed to the observed overall imbalance in cancer cases.
We are investigating possible Belviq lawsuits that involve patients on Belviq developing cancer. At the present time, our focus for these Belviq lawsuits is pancreatic cancer, colon cancer, rectal cancer, and lung cancer cases. Let us know if we can help you or a family member by submitting an online Belviq Case Evaluation form, sending me an email, or calling us (800-426-9535).
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review is done by attorney Tom Lamb)